The Evolution of HTA in Emerging Markets Health-Care ... - TREE

OHE Consulting Report for PhRMA
5 January 2011
Appendix 5: Interview Programme
The Table below represents local experts identified as potential targets to interview for each country. In total 19 experts were interviewed from this list
across the three countries. For China the names highlighted in bold represent those whom were interviewed. For Brazil the interviews were conducted on
the basis of non-­‐disclosure of their names. Similarly for Taiwan, those names represent those determined as potential targets for interview, but the specific
subset who was interviewed has not been disclosed.
China
Academic Government Industry Other
Dr. Gordon Liu, Professor of
Economics, Guanghua School of
Management, Peking University.
Dr. Shanlian Hu, Professor of
Epidemiology and Health
Management, School of Public
Health, Fudan University
Dr. Zhenzhong Zhang, Director of
China Health Economics Institute,
Ministry of Health.
Lu Fengxia, Chairman, Drug Price
Evaluation Center, NDRC
Dr. Vivian Chen, Director of Healthcare
Economics, R&D-­‐based Pharmaceutical
Association Committee
Dr. Chuan Chen, Director of Government
Affairs, Xian-­‐Janssen Pharmaceutical Ltd.
Dr. Jiuhong Wu, Director of Pharmacy
Department, the 306th Hospital of PLA.
Ashoke Bhattacharjya within JnJ. He is
within the Health Policy team
Manny Papadimitropoulos (Regional Director
of Health Outcomes for Lilly in Emerging
Bill Montgomery and / or Narayan Rajan
(works out of Australia for Manny and also
has great technical knowledge of these
developing markets)
Guang Zhiqiang, GAD, Pfizer
David Banta – although
not based in China,
helped establish HTA in
China
107